One of the factors of male infertility is idiopathic oligospermia in which the causative factor is not known. A direct case control, two-centers, prospective, randomized controlled two-arm parallel group trial was carried out to investigate the safety and efficacy of trialed medicine in Shifa-ul-Mulk Memorial Hospital for Eastern Medicine at Madinat-ul-Hikmah, Hamdard University Karach-74600, Pakistan. An assessment was conducted on the coded herbal formula Spermox (Test drug) to treat idiopathic condition of oligospermia; the test drug spermox was compared with Fertilox (Control drug). The idiopathic pathogenic states of spontaneous origin were detected on 62 clinically diagnosed patients. The conclusive findings were significant as improvements were seen in clinical assessment and semen analyses parameters. The value of sperm count per milliliter in spermox was found more than 29 million in 26 patients (p 0-032). It revealed that Spermox is more effective in upgrading the semen quality and quantity when compared with Fertilox for the treatment of idiopathic oligospermia. This is clearly evident that Spermox (Test drug) possesses a more viable value for the treatment of idiopathic oligospermia in comparison to Fertilox (Control drug).
Key words: Oligospermia, herbal medicine, male infertility, prospective, multicentre, randomized, clinical trial.
Copyright © 2021 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0